prosthetic heart valves

in review 6 min read Updated 2026-11-19
prosthetic heart valves

Mechanical valve → lifelong warfarin; never DOAC. Bioprosthetic valve → no long-term anticoagulation unless another indication; after TAVI → ASA alone. Mechanical lasts but needs warfarin; tissue valves avoid warfarin but degenerate — so younger patients get mechanical, older patients tissue. Any prosthesis (including TAVI) → endocarditis prophylaxis before dental extractions. A rising gradient → compare with the baseline echo and find the cause (thrombosis, pannus, degeneration, mismatch, high flow, endocarditis); a mechanical valve with pulmonary oedema or shock → thrombosis until proven otherwise.


choice of prosthesis

MechanicalBioprosthetic
durabilitylifelongdegenerates (faster in the young) → reintervention
anticoagulationlifelong warfarinnone long term
favoured inyounger patients, already on warfarinolder patients, high bleeding risk, unreliable INR control, women planning pregnancy

Age guide (aortic): mechanical <50, either 50–65, bioprosthetic >65 (ACC/AHA); ESC uses <60 and >65.


mechanical valves

no DOACs for mechanical valves

Dabigatran (RE-ALIGN) and apixaban (PROACT-Xa) → more valve thrombosis than warfarin. Any position.

ValveINR target
aortic, modern bileaflet, no risk factors2.5 (2.0–3.0)
aortic + risk factor (AF, LV dysfunction, prior embolism, hypercoagulable)3.0 (2.5–3.5)
mitral or tricuspid3.0 (2.5–3.5)
On-X aortic valve (>3 months, no AF/extra stroke risk factor)1.5–2.0 + ASA (ACC/AHA 2b; Thrombosis Canada “may be candidates”; not endorsed by ESC 2025, which allows 2.0 [1.5–2.5] if high bleeding risk)
  • mitral valves are more thrombogenic (low-pressure inflow) → higher target
  • add low-dose ASA only if another indication (e.g. CAD) and bleeding risk is low, or embolism despite therapeutic INR
  • minor procedures (dental extraction, cataract, skin, device implant) → continue warfarin
  • major surgery → stop warfarin before surgery and restart once bleeding risk allows (timing → periprocedural anticoagulation); bridge with LMWH/UFH for mechanical valves (Thrombosis Canada: all; ESC IIa: those with thromboembolic risk factors) — new-generation aortic valve without other risk factors → interruption without bridging may be considered (ESC IIb; ACC/AHA I for bileaflet AVR)
  • bleeding → anticoagulant reversal

bioprosthetic valves

No other indication for anticoagulation:

  • TAVI → ASA 81 mg alone — 12 months (ESC I), then lifelong (ESC IIa). No routine DAPT or anticoagulation; if OAC needed (e.g. AF) → OAC alone — POPular TAVI (2020): adding clopidogrel only added bleeding
  • surgical bioprosthesis: aortic or mitral → warfarin (INR 2.5) for 3–6 months or ASA 81 mg; tricuspid/pulmonic → warfarin for 3 months or ASA (Thrombosis Canada). Afterwards lifelong low-dose ASA may be considered

With AF or another indication:

  • anticoagulate as usual — DOAC acceptable (typically after the first 3 months for surgical valves)
  • TAVI + AF → anticoagulant alone, no added antiplatelet

follow-up: compare with the baseline echo

  • baseline TTE after implant (before discharge or within 1–3 months) → the reference for every later gradient. A gradient means little without it
  • mechanical valve → INR monitoring and clinical review; repeat imaging only if symptoms or signs change
  • bioprosthetic valve → routine TTE for degeneration. ESC: at 1 year, then yearly. ACC/AHA: surgical valves at 5 and 10 years, then yearly; TAVI yearly
  • new symptoms, a new murmur or muffled mechanical clicks → TTE now. Suspected dysfunction with a normal TTE → TOE, gated CT or fluoroscopy anyway

prosthetic valve dysfunction: why is the gradient high?

New dyspnoea, heart failure, an embolic event or a rising gradient → work out the cause before treating the number. Obstruction ≈ mean gradient up >50% from baseline (aortic: >10 mmHg) once high flow is excluded (ACC/AHA). Don’t call stenosis on one number: pair a gradient or velocity with a less flow-dependent measure (EOA or DVI) (ASE). Symptomatic severe prosthetic stenosis → redo surgery, or valve-in-valve if surgical risk is high.

CauseCluesNext step
valve thrombosismechanical valve with subtherapeutic INR or missed doses; sudden onset, embolism; restricted leaflet on fluoroscopy/TOE→ below
pannusslow rise over years; INR has been therapeuticcontrast CT: pannus is late and high attenuation, thrombus early and low (they can coexist) → surgery if obstructive
structural degeneration (bioprosthesis)gradual rise, years out; leaflet calcification or tearvalve centre → redo surgery or valve-in-valve TAVI
prosthesis–patient mismatchgradient high from the first echo, not risingrarely needs reoperation
high-flow stateanaemia, fever, sepsis, pregnancytreat the cause, repeat echo
endocarditisfever, bacteraemia, new regurgitation, new conduction blockcultures before antibiotics, TOE → infective endocarditis
paravalvular leakregurgitation around the sewing ring; haemolysis (↑LDH, ↓haptoglobin, schistocytes)intervene for symptoms or transfusion-requiring haemolysis (surgical or transcatheter closure)
obstructive mechanical valve thrombosis

Acute pulmonary oedema or shock with a mechanical valve → assume thrombosis. Heparin now, emergency TOE plus fluoroscopy or CT for leaflet motion, and Heart Team. Emergency surgery (shock, large thrombus, possible pannus, recurrence, contraindication to lysis) or low-dose slow-infusion fibrinolysis (high surgical risk, right-sided valve). Non-obstructive thrombus → optimise anticoagulation, re-image; surgery if large (≥10 mm) with embolism.

Bioprosthetic valve thrombosis (rising gradient, thickened leaflets on TOE/CT; commonest in first 3 months, seen up to a few years out, commoner after TAVI):

  • stable with raised gradient or confirmed thrombus → VKA first, then repeat imaging
  • tends to recur → indefinite anticoagulation may be considered (ESC), weighed against bleeding
  • incidental leaflet thickening on CT with normal gradients → significance uncertain, no routine treatment and no routine CT screening

endocarditis prophylaxis

Any prosthetic valve — including TAVI — prosthetic repair material, or prior IE → antibiotic prophylaxis for dental procedures manipulating the gingiva (extractions, oral surgery). Not for cleaning without gingival manipulation, GI/GU procedures or TOE → regimens in infective endocarditis.


pregnancy

Mechanical valves in pregnancy → high thrombotic risk, and warfarin is teratogenic → bioprosthesis preferred in women planning pregnancy; management → heart disease in pregnancy.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction prosthetic heart valves